MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study

October 22, 2026

Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable Tolerability

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

Performance

52-Week Range 67.5% below 52-week high

0.5500

0.5152W Low 1.6952W High

1 Week 8.3% below 1-week high

0.511W Low 0.601W High

MIRA Pharmaceuticals, Inc. - Common Stock (MIRA) traded between $0.51 and $1.69 over the past 52 weeks and last traded at $0.55, 67.5% below its 52-week high. Over the past week it ranged between $0.51 and $0.60.

Past 12 Months

+2.4%

-26.2%

-28.3%

-44.4%

-63.1%

-62.3%

1W +$0.01

1M -$0.20

3M -$0.22

6M -$0.44

YTD -$0.94

1Y -$0.91

MIRA was -62.3% over the past year, -44.4% over six months, -63.1% year to date, +2.4% in the last week.

12 Months vs Market

MIRA

-62.3%

DIA

+9.3%

SPY

+9.1%

QQQ

+6.8%

IWM

+13.5%

Over the past 12 months MIRA returned -62.3% versus DIA (Dow) +9.3%, SPY (S&P 500) +9.1%, QQQ (Nasdaq 100) +6.8% and IWM (Russell 2000) +13.5%.

Volume & Liquidity 0.01× 3-mo avg

Today 3,240 3-mo avg 598.8K

87.6K

143.8K

598.8K

355.7K

YTD

272.4K

268.8K

MIRA most recently traded 3,240 shares against a 3-month average daily volume of 598.8K.

More News

Thursday's session: gap up and gap down stocks ↗

October 01, 2026

Via Chartmill

September 17, 2026

Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? ↗

September 01, 2026

Via Benzinga

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

September 01, 2026

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

August 06, 2026

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

July 30, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

July 10, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

July 06, 2026

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

June 25, 2026

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

June 17, 2026

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

June 04, 2026

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

May 27, 2026

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

May 14, 2026

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

May 13, 2026

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Wondering what's happening in today's after-hours session? ↗

April 01, 2026

Via Chartmill

What's Going On With MIRA Pharma Stock Tuesday? ↗

March 24, 2026

Via Benzinga

March 23, 2026

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

March 04, 2026

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

February 03, 2026

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

October 24, 2025